Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission
Conditions
Interventions
Oral Azacitidine
Placebo
Locations
223
United States
Arizona Oncology Associates, P.C.
Phoenix, Arizona, United States
Providence St Joseph Medical Center Cancer Center
Burbank, California, United States
City Of Hope
Duarte, California, United States
University of California San Francisco Fresno Campus
Fresno, California, United States
University of Southern California Norris Cancer Center
Los Angeles, California, United States
Local Institution - 006
Los Angeles, California, United States
Start Date
April 24, 2013
Primary Completion Date
July 15, 2019
Completion Date
June 18, 2024
Last Updated
July 8, 2025
NCT06852222
NCT06580106
NCT06501196
NCT06384261
NCT06382168
NCT06118788
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions